



NDA 21-664

ISTA Pharmaceuticals, Inc.  
Attention: Marvin Garrett  
Vice President, Regulatory Affairs,  
Quality & Compliance  
15279 Alton Parkway  
Suite 100  
Irvine, CA 92618

Dear Mr. Garrett:

Please refer to your new drug application (NDA) dated May 24, 2004, received May 26, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for XIBROM (bromfenac ophthalmic solution) 0.09%.

We acknowledge receipt of your submissions dated July 7, August 13, September 23, October 22(two), and November 3, 2004, and January 27, February 2, 22 and 24, and March 4, 9, 10(two), 15 and 17, 2005.

This new drug application provides for the use of XIBROM (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation in patients who have undergone cataract extraction.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed draft package insert submitted March 17, 2005. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

The electronic labeling rule published December 11, 2003, (68 FR 69009) requires submission of labeling content in electronic format effective June 8, 2004. For additional information, consult the following guidances for industry regarding electronic submissions: *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999) and *Providing Regulatory Submissions in Electronic Format – Content of Labeling* (February 2004). The guidances specify that labeling is to be submitted in *pdf* format. To assist in our review, we request that labeling also be submitted in MS Word format. If formatted copies of all labeling pieces (i.e., package insert, container labels, and carton labels) are submitted electronically, labeling does not need to be submitted in paper.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional and educational materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anti-Inflammatory, Analgesic, and Ophthalmic Drug Products, and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,  
and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Raphael R. Rodriguez, Regulatory Project Manager, at (301) 827-2090.

Sincerely,

*{See appended electronic signature page}*

Wiley A. Chambers, M.D.  
Deputy Director  
Division of Anti-Inflammatory, Analgesic,  
and Ophthalmic Drug Products, HFD-550  
Office of Drug Evaluation V  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Wiley Chambers  
3/24/05 03:51:08 PM